NantHealth and our payer partners have collaborated to provide a list of resources to help our customers care for patients who may be impacted by COVID-19
Resources from NantHealth
VIDEOS: THE SCIENCE BEHIND COVID-19
In a video series for the @latimes, NantHealth CEO Dr. Patrick Soon-Shiong explores the science behind COVID-19.
• Series I: How COVID-19 infects our bodies, how it spreads and how you can protect yourself and those around you. Watch Series I here.
• Series II: The three stages of infection, treatment strategies and the race for the vaccine. Watch Series II here.
LIVE RECORDED WEBINARS
Thursday, April 9 at 12 pm ET we hosted a live webinar with NantHealth’s Chief Medical Officer, Dr. Bobby Reddy, and Eviti’s Chief Medical Officer, Dr. Bill Flood, presenting an evidence-based look at oncology care in the COVID-19 pandemic. Watch the recording of the webinar here.
Thursday, May 14 at 12 pm ET we hosted a live webinar with NantHealth’s Chief Medical Officer, Dr. Bobby Reddy, and expert panelists from ImmunityBio and NantKwest, on the science and treatment of COVID-19. Watch the recording of the webinar here.
Through our #GiveThanks initiative, NantHealth honors the healthcare staff and administrative workforce on the front lines providing care and services for patients during this global crisis. We honor you.
NANTHEALTH CHAIRMAN AND CEO DR. PATRICK SOON-SHIONG FEATURED ON FOX BUSINESS FOR REVOLUTIONARY CANCER EXPERIMENTAL DRUG, ALSO FOCUSING ON CORONAVIRUS VACCINE
“Doctor who treated former Nevada Sen. Harry Reid’s cancer now focusing on coronavirus”
Two of Dr. Soon-Shiong’s companies, ImmunityBio and NantKwest, are partnering on a coronavirus vaccine as part of the Department of Health and Human Services’ Operation Warp Speed.
Read the story here: foxbusiness.com/lifestyle/coronavirus-doctor-harry-reid-cancer
CONTAGION LIVE INTERVIEW WITH NANTHEALTH AND IMMUNITYBIO CHAIRMAN AND CEO DR. PATRICK SOON-SHIONG ON CORONAVIRUS VACCINE CANDIDATE
“SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?”
Dr. Patrick Soon-Shiong explains why ImmunityBio’s SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.